SSRI CHINA news

SSRI has been conducting healthcare-related market research in China since 2003, and we established our regional office, SSRI CHINA Co., Ltd., in 2012.

With our wealth of experience, we have created a brief introduction to the Chinese healthcare market with some tips on how to design and conduct healthcare-related market research in China. The information may also help you better understand and interpret the study findings of this unique market.

• - Geographical & population background
• - General economic situation
• - Healthcare institutions and hospital tiers
• - HCP landscape
• - Healthcare expenses & cost structure
• - Medical insurance system
• - NMPA approval and NRDL listing
• - Western pharmaceutical market concentration
• - Notes about healthcare market research in China

You can download the introduction file from here:

Introduction to the Chinese healthcare market

• Once you click the link, a pop-up with an explanation on how we handle personal information will appear. Click “I agree”, and then enter your name, email address and company name, and then click “Submit”. Then, a page will appear where you can download the file.

On July 2nd, 2026, SSRI and M3 launched the 2026 version of PatientsMap China

Introduction to PatientsMap CN:

PatientsMap CN is a database product which uncovers the types of diseases that various specialists manage, and the monthly patient volume for each disease. The data is collected from around 10,000 physicians covering approximately 400 diseases/conditions.

PatientsMap can also be used as a tool for estimating nationwide patient numbers for various diseases across, not only different specialties, but also by hospital tiers and city tiers. It can help you in analyzing the potential of a new drug and also targeting the appropriate specialties in terms of market research and/or for promotional purposes.

This 2026 version is the fourth installment of PatientsMap China, with previous rounds conducted in 2018, 2019 and 2022. PatientsMap is also conducted in Japan (annually) and in the US (every 2 years).

Outline of PatientsMap 2026 China:

1. Product name:    PatientsMap 2026 CN
2. Objective:    To understand the treatment condition of various specialists
3. Number of studied diseases:    420
4. Sample size:    10,112 physicians from various departments
5. Methodology:    Online survey
6. Survey region:    Nationwide

Contents of PatientsMap 2026 China:

• > Total number of patients that they see (per month)
• > Diseases/conditions that they see (420 disease types)
  •    - Number of patients they see for each disease/condition
  •    - Number of patients in which they prescribe medications for that disease/condition
  • > Diseases in which they wish for new product development
• > Promotional activities of manufactures (65 manufacturers)
  •    - Manufacturers they had face to face meetings with sales reps
  •    - Manufacturers they had remote meetings with sales reps
  •    - Manufacturers that have provided them with information via online
  •    - Manufacturers they consider reliable
  • > Demographics
•    - Primary specialty
•    - Province and city of the practice
•    - Hospital type and tier level
•    - Number of beds at the hospital
•    - Title / position
•    - Age range

For more information on PatientsMap, please contact;  patientsmap@ssri.com